ArticleAlimentary pharmacology & therapeutics2026
Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Characteristics and predictive factors of recompensation in patients with hepatitis B-related decompensated cirrhosis: a retrospective cohort study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- [Clinical research progress in 2025 for hepatic fibrosis, cirrhosis, and portal hypertension].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
BACKGROUND AND
aimRecent studies show that patients with hepatitis B virus (HBV)-related decompensated cirrhosis who achieve recompensation can still experience further decompensation, suggesting that recompensation status can change over time. This study aimed to classify patterns of recompensation and charaterize the clinical differences among these subgroups.
methodsEligible patients with HBV-related decompensated cirrhosis were enrolled from two cohorts. Clinical characteristics and complications were assessed every 6 months for up to 5 years following their first episode of decompensation. Recompensation was defined according to the Baveno VII criteria and further categorised as stable (no subsequent decompensation) or unstable (recurrent decompensation or recompensation following multiple decompensation episodes).
resultsA total of 378 patients were included; 294 (77.8%) achieved recompensation, while 84 (22.2%) did not. After a median follow-up of 5.3 years (IQR 4.4-5.8), recompensated patients were classified into stable recompensation (202/378, 53.4%) and unstable recompensation (92/378, 24.3%). The 5 year rate of hepatocellular carcinoma (HCC) or all-cause mortality was higher in the unstable group than the stable group (14.7% vs. 10.1%, p = 0.038), yet remained lower than in patients with ongoing decompensation. Liver function improvement was intermediate in the unstable group compared with the stable recompensation and ongoing decompensation. Logistic regression yielded the highest accuracy for predicting recompensation (AUROC = 0.884), while support vector machine algorithms best predicted stable recompensation (AUROC = 0.911).
conclusionRecompensation is not a uniform condition and should be further subclassified. Unstable recompensation is a distinct state with poorer survival than stable recompensation, yet better outcomes than ongoing decompensation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.